Welcome to our dedicated page for Adagene news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.
Adagene Inc (NASDAQ: ADAG) is a clinical-stage biopharmaceutical pioneer leveraging AI and proprietary platforms like SAFEbody® to develop precision antibody therapies for cancer. This page provides investors and industry professionals with timely updates on material developments, including clinical trial progress, strategic collaborations, and regulatory milestones.
Access authoritative updates on ADAG’s antibody discovery pipeline, including its lead candidate ADG126 targeting colorectal cancer. The repository consolidates press releases, financial disclosures, and research breakthroughs related to the company’s Dynamic Precision Library technology and therapeutic innovations.
Key content categories include clinical trial results, partnership announcements with global biopharma leaders, and updates on novel platforms addressing on-target off-tumor toxicity challenges. All materials adhere to factual reporting standards, providing stakeholders with reliable data for informed analysis.
Bookmark this page for streamlined access to Adagene’s latest developments in computational antibody engineering. Check regularly for updates on how ADAG’s masked antibody therapies are redefining safety and efficacy standards in oncology.
Adagene Inc. (Nasdaq: ADAG) reported financial results for H1 2024 and provided corporate updates. Highlights include:
1. ADG126, a masked anti-CTLA-4 SAFEbody, shows potential best-in-class profile in combination with pembrolizumab.
2. Poster presentation planned at ESMO Congress 2024 for ADG126 in metastatic MSS colorectal cancer.
3. Cash balance of $95.7 million funds operations into 2026.
4. Net revenue was nil for H1 2024, compared to $17.3 million in H1 2023.
5. R&D expenses decreased 31% to $14.7 million in H1 2024.
6. Net loss was $17.0 million in H1 2024, compared to $4.1 million in H1 2023.
7. Non-GAAP net loss was $14.5 million in H1 2024.
Adagene has announced a poster presentation at the European Society for Medical Oncology (ESMO) Congress, scheduled for 13-17 September 2024 in Barcelona, Spain.
The presentation will highlight results from an ongoing phase 1b/2 trial of their masked anti-CTLA-4 SAFEbody, ADG126 (muzastotug), in combination with pembrolizumab. The trial focuses on treating patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The poster, titled 'Increased Therapeutic Index of Muzastotug (Muza, ADG126), a Masked Anti-CTLA-4 SAFEbody, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC', will be available on Adagene's website following ESMO's embargo policy.
Adagene (Nasdaq: ADAG) will participate in multiple investor conferences in June 2024. CEO and Chairman, Peter Luo, Ph.D., will provide company updates, particularly on the ADG126 SAFEbody® anti-CTLA-4 progress. The Jefferies Global Healthcare Conference in New York City is scheduled for June 5, followed by the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 13. Lastly, the HC Wainwright 2nd Annual Immune Cell Engager Virtual Conference will be held on June 25. Investors can access live webcasts and replays on Adagene's website.
FAQ
What is the current stock price of Adagene (ADAG)?
What is the market cap of Adagene (ADAG)?
